Lytix Biopharma names Timothy Herpin chief business officer

• Lytix Biopharma appointed Timothy F. Herpin as chief business officer on a fractional basis, effective Aug. 17, 2026.
• Herpin will lead global business development, partnering activity, and execution of the company’s partnering strategy with senior management.
• He founded Anza Advisors, providing fractional CBO services to biotech companies.
• Herpin previously served as CBO at Santa Ana Bio, supporting a USD 125 million Series B, and at Caribou Biosciences.
• He was vice president and head of transactions, business development at AstraZeneca, with earlier senior roles at Johnson & Johnson and Bristol Myers Squibb.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260818:BIT:8848:0) on August 18, 2026, and is solely responsible for the information contained therein.